FOLFIRINOX in Patients With Inoperable Pancreatic Cancer

Inclusion Criteria: * Histologically or cytologically confirmed locally advanced unresectable or borderline resectable adenocarcinoma of pancreas * Patients must have measurable disease as defined by RECIST 1.1 RECIST evaluations must have occurred within 4 weeks prior to study entry * No evidence of hepatic or pulmonary metastatic disease by CT or CT/PET scans * Male or non-pregnant and non-lactating female age \> or equal to 18 years and \< or equal to 70 years of age * Patient must have received no prior therapy for the treatment of locally advanced unresectable or borderline resectable pancreatic cancer * Patients must have adequate blood counts at baseline and blood chemistry levels * Patient has ECOG Performance Status 0 to 1 Exclusion Criteria: * Patients with islet cell neoplasms excluded * Patients with known brain metastases * Therapeutic Coumadin for a history of pulmonary emboli or deep vein thrombosis (DVT) * Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy * Known infection with HIV, hepatitis B or hepatitis C * Major surgery or vascular device placement within 4 weeks prior to Day 1 of treatment in study * Prior chemotherapy or radiation for pancreatic cancer * History of allergy or hypersensitivity to the study drugs * Patient is enrolled in any other clinical protocol or investigational trial * Metastatic disease on radiological staging * Prior malignancy within last 3 years * Significant cardiac disease * Any prior gastrointestinal (GI) disease or history of prior pelvic or abdominal radiation in which in opinion of the investigator may place the patient at increased risk * peripheral sensory neuropathy \> or equal to grade 2 at baseline